Aptera Motors announced a significant reduction in its estimated capital requirements to reach production, lowering the target to $25 million from a previous estimate of $40-$45 million. The company attributes these savings to its strategic partnership with Launch Design, which improved manufacturability and supplier access, and now expects to begin building its first 40 production vehicles by the end of 2026.
Counterparty
Shanghai Launch Automotive Technology Co., Ltd.
“This is a fundamentally leaner path to getting Aptera into customers’ hands. We’ve reduced our estimated capital requirements to reach production and brought what we believe could be a self-sustaining business within much closer reach.”
Chris Anthony, Co-CEO of Aptera
“By redesigning the Aptera for manufacturability and tapping Launch Design’s international supplier network, we believe we are pursuing one of the more capital-efficient paths to production in the EV industry.”
Allarity Therapeutics provided an operational update regarding its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company highlighted that higher DRP scores were associated with longer overall survival in ovarian cancer patients treated with stenoparib, supporting its strategy to use the technology for patient selection in upcoming pivotal trials.
Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.
FrontView REIT provided an operational update for Q3 2026, reporting the acquisition of 16 properties for $50.6 million at a 7.6% yield and the sale of 5 properties for $17.1 million. The company also disclosed capital markets activity, including the settlement of ATM forward shares for $32.7 million and the issuance of $20.0 million in Series A Convertible Preferred Stock.
Magnolia Oil & Gas provided an interim operational update following the closing of its WildFire Energy acquisition, noting that integration is on track to realize $100 million in annual synergies. The company also optimized its portfolio by selling non-core assets in Dimmit and Zavala counties for $47.5 million while increasing its working interest in the Karnes area. Magnolia reported ending Q3 2026 with approximately $1.9 billion in net debt, achieving leverage targets more than a year ahead of schedule.
Cheetah Net Supply Chain Service Inc. provided an update on its at-the-market (ATM) offering, disclosing the sale of approximately 196.85 million shares of Class A common stock as of September 25, 2026. The company also confirmed its post-split share count following a 1-for-150 reverse stock split that became market effective on September 28, 2026, resulting in approximately 1.33 million Class A shares outstanding.
Pacific Coast Oil Trust announced there will be no cash distribution for the month of September 2026 based on net profits generated during July 2026. The Trust noted that future distributions are extremely remote as it faces dissolution due to annual proceeds falling below $2.0 million and ongoing legal proceedings regarding asset retirement obligations.
MoonLake Immunotherapeutics has submitted a Biologics License Application (BLA) to the FDA for its tri-specific nanobody sonelokimab. The application seeks approval for the treatment of moderate-to-severe hidradenitis suppurativa in adults and pediatric patients. The company expects notification regarding the acceptance of the BLA for review within approximately 60 days.
ProText Mobility issued an inter-quarter shareholder update announcing that its Chairman has been confirmed as the first pilot client for ABSA Bank's digital-asset custody onboarding process. This pilot participation is a key milestone in the company's strategy to integrate its SVLT tokenization technology with regulated institutional financial infrastructure as it prepares for a potential uplisting to a national securities exchange.
bioAffinity Technologies and its distribution partner AvMEDICAL debuted their joint exhibition of the CyPath Lung cancer test at the NAVREF 2026 Annual Conference. The update highlights progress under a previously announced distribution agreement aimed at expanding veteran access to noninvasive lung cancer testing through federal procurement channels.
Getty Images Holdings, Inc. announced that it has made the interest payments for its 9.750% Senior Notes due 2027 and 14.000% Senior Notes due 2028 within the 30-day grace period. By making these payments before the deadline, the company avoided an 'Event of Default' under the governing indentures. The company continues to evaluate strategic financing alternatives and maintain dialogue with debt and equity holders regarding its balance sheet.
ACM Research's operating subsidiary, ACM Research (Shanghai), reported a total backlog of RMB 17.1 billion ($2.5 billion) as of September 29, 2026. This represents an 88.2% year-over-year increase and includes both shipped tools awaiting revenue recognition and future orders. The disclosure was made in accordance with reporting requirements for the Shanghai Stock Exchange.
AEON Biopharma received official minutes from a Type 2b meeting with the FDA regarding the biosimilar development pathway for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with a proposed two-stage pharmacodynamic study design, and the company plans to submit an IND for this study in Q4 2026 with initiation expected in Q1 2027. The feedback supports a potentially streamlined development path that may leverage existing comparative human evidence to avoid or narrow the scope of standalone comparative efficacy studies.
Artificial Intelligence Technology Solutions Business Update
Artificial Intelligence Technology Solutions' subsidiary, RAD, received an additional order for one RIO 360 unit from an existing global healthcare technology client. This follows a previous order from the same customer earlier in the month and is intended for after-hours trespass deterrence at a second location.
Ares Management Corporation provided a preliminary estimate for its realized net performance income for the third quarter ending September 30, 2026. The company expects approximately $10 million in realized net performance income, a slight increase from the $9 million reported in the same period the prior year.
Sable Offshore Corp. provided an operational update regarding the pending restart of Platform Hondo, noting that reconstruction is complete and final regulatory approval from the Marine Minerals Administration is expected in October 2026. The company is also upgrading its Las Flores Canyon facility to increase processing capacity and reported preliminary September oil sales of approximately 34,000 gross barrels per day.
VanEck BNB ETF has amended its custodial agreement with BitGo to appoint Figment as the validator for the Trust's BNB staking activities. The amendment establishes a 4% staking assets validator fee for these services.
Meridian Holdings provided an update regarding a new Provisional Measure in Brazil that prohibits online betting and casino services and requires the return of funds to bettors. The company confirmed that Brazil represents an immaterial share of its group revenue and that it has been fully compliant with the new regulatory requirements. The measure is currently provisional and requires approval by the Brazilian Congress within 120 days to remain in effect.
United States Commodity Index Funds Trust Business Update
United States Commodity Index Funds Trust released monthly account statements for its USCI and CPER funds for the period ended August 31, 2026. The USCI fund reported net income of $19.1 million with a month-end NAV per share of $106.42, while the CPER fund reported net income of $15.8 million with a month-end NAV per share of $40.02.
United States Brent Oil Fund, LP issued its monthly account statement for August 2026, reporting a net income of $35.07 million. The fund's net asset value (NAV) ended the month at $620.94 million, or $52.85 per share, reflecting realized and unrealized gains on commodity futures.
United States Gasoline Fund, LP issued its monthly account statement for August 2026, reporting a net income of $10.59 million. The fund's net asset value (NAV) ended the period at $146.96 million, or $127.79 per share, reflecting realized and unrealized gains on commodity futures trading.
United States 12 Month Oil Fund, LP issued its monthly account statement for August 2026, reporting a net income of $2.13 million. The fund ended the period with a Net Asset Value (NAV) of $44.49 million, or $52.34 per share, after accounting for $2.61 million in share withdrawals.
United States Natural Gas Fund, LP (UNG) issued its monthly account statement for August 2026, reporting a net income of $30.05 million. The fund's Net Asset Value (NAV) ended the period at $570.97 million, or $10.55 per share, following $106.1 million in share additions and $41.2 million in withdrawals.
United States Oil Fund, LP (USO) issued its monthly account statement for August 2026, reporting a net income of $84.02 million. The fund's Net Asset Value (NAV) ended the month at approximately $1.79 billion, or $133.38 per share, following $1.12 billion in share additions and $1.26 billion in withdrawals.
Fidelity Core Real Estate Fund released its August 31, 2026 fact sheet, reporting a Net Asset Value (NAV) per share of $11.57 and an annualized net total return of 8.85% since inception. The update provides a breakdown of the fund's portfolio allocation across industrial, residential, and retail sectors, along with monthly performance metrics for the year to date.
Greenland Energy Company issued a shareholder letter responding to a short-seller report from Fugazi Research that labeled the company uninvestable. The company clarified its status as an exploration-stage firm with no current production and defended its financial position, noting it raised $70 million in cash and that its 'burn rate' was inflated by one-time capitalized asset acquisitions.
Host Digital issued a shareholder letter following its recent merger and public listing to outline its strategy as a vertically integrated digital infrastructure company. The company focuses on 'RightScaled' data centers (20-100 megawatts) for AI and HPC workloads, with a pipeline of four additional sites totaling over 450 megawatts of potential capacity targeted for delivery by the end of 2027.
NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.
Allarity Therapeutics has expanded its in-house medical laboratory capabilities to include proteomics and cell line research. These new capabilities will support deeper mechanism-of-action research for its lead asset, stenoparib, and allow the company to offer a broader range of research services to external partners. The expansion is expected to create cost efficiencies without impacting the company's current cash runway.
Ameren Missouri filed its 2026 Integrated Resource Plan (IRP) with the Missouri Public Service Commission, outlining a preferred plan to meet projected energy demand growth of up to 9 GW by 2045. The plan includes significant investments in natural gas-fired generation, solar, wind, battery storage, and new nuclear generation, while extending the life of certain coal units and retiring others. Key targets include adding 2,100 MW of combined-cycle gas by 2031 and 2,400 MW of battery storage by 2030.